Trial ID or NCT#

NCT02438826

Status

recruiting iconRECRUITING

Purpose

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.

Official Title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Nada Hindiyeh, MD
Nada Hindiyeh, MD
Headache specialist
Clinical Associate Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.

CONTACT


(650) 723-5184